Financial Performance - The net loss for the six months ended June 30, 2024, was £13.83 million, compared to a loss of £13.28 million for the same period in 2023, reflecting a 4.1% increase in losses[5] - The total comprehensive loss for the six months ended June 30, 2024, was £13.83 million, compared to £13.32 million for the same period in 2023, indicating a 3.8% increase in comprehensive losses[5] - Operating loss for Q2 2024 was £8.35 million, compared to £6.28 million in Q2 2023, reflecting a 33% increase in operating losses[4] - For the three months ended June 30, 2024, the Company reported a loss of £6.995 million, compared to a loss of £5.414 million for the same period in 2023, resulting in a basic and diluted loss per share of £0.12[28] Cash and Cash Equivalents - Cash and cash equivalents decreased to £11.64 million as of June 30, 2024, down from £17.23 million at the end of 2023, representing a decline of 32.5%[7] - Cash and cash equivalents decreased to £11.639 million as of June 30, 2024, down from £17.225 million as of December 31, 2023[31] - The Company has a going concern period of 12 months, but current cash and cash equivalents are insufficient to fund anticipated operations during this period, necessitating additional capital[23] - There is substantial doubt about the Company's ability to continue as a going concern due to uncertainty in raising sufficient additional capital before cash balances are exhausted[24] Research and Development - Research and development expenses for Q2 2024 were £6.77 million, an increase of 71% compared to £3.96 million in Q2 2023[4] - The Company recognized an income tax credit of £1.272 million for the three months ended June 30, 2024, primarily from U.K. research and development tax credits[26] Share Capital and Equity - Share capital as of June 30, 2024, was £2,266,200, and as of December 31, 2023, it was £2,114,000, indicating an increase of approximately 7.2%[37] - The premium share capital was £1,426,604 as of June 30, 2024, compared to £1,413,430 as of December 31, 2023, reflecting a growth of about 0.9%[37] - The exercise of share options resulted in an issuance of share capital of £3,740,015, which shows active management of equity compensation[37] - The balance at June 30, 2024, was £5,566,660, compared to £2,266,140 as of December 31, 2023, representing a significant increase in total equity[37] Assets and Deficits - Total assets decreased to £20.07 million as of June 30, 2024, from £27.81 million at the end of 2023, a decline of 27.7%[7] - The accumulated deficit reached £219.44 million as of June 30, 2024, up from £207.71 million at the end of 2023, marking a 5.7% increase[7] - The Company has a deferred tax asset of £168,000 as of June 30, 2024, compared to £143,000 as of December 31, 2023[27] Revenue Generation - The company has not generated any revenues from operations to date and does not expect to in the foreseeable future, indicating ongoing financial challenges[22] Share Options - The Company granted 6,273,782 share options under the 2020 Long-Term Incentive Plan during the six months ended June 30, 2024, compared to 2,695,639 options granted in the same period of 2023[33] - Share-based payment expense for the three months ended June 30, 2024, was £0.7 million, a decrease from £1.1 million for the same period in 2023[36]

Key Data Readouts on Track for All Programs in 2024 Anticipated Cash Runway into Q1 2025 EDINBURGH, United Kingdom, Aug. 15, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2024 and provided an update on its broad clinical development program with its transformative ProTide therapeutics. As of June 30, 2024, NuCana had cash and cash equivalents of £11.6 million compared to £12.9 million as of March 31, 2024 and £17.2 million at December 31 ...

About NuCana NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, they have significant shortcomings that limit their efficacy and they are of ...

NuCana plc Hugh S. Griffith Chief Executive Officer +44 131 357 1111 info@nucana.com ICR Westwicke Chris Brinzey +1 339-970-2843 chris.brinzey@westwicke.com About NuCana NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part o ...

NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, they have significant shortcomings that limit their efficacy and they are often poorly to ...

EDINBURGH, United Kingdom, May 21, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present at TD Cowen's 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Event: TD Cowen's 5th Annual Oncology Innovation Summit Date: Tuesday, May 28, 2024 Time: 8:30 AM EDT Location: Virtual The presentation will be webcast live and available for replay under "Events & Presentations" in the Investors sec ...

Exhibit 99.1 NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION AS AT | | | March 31, | December 31, | | --- | --- | --- | --- | | | | 2024 | 2023 | | | | (in thousands) | | | Assets | Notes | £ | £ | | Non-current assets | | | | | Intangible assets | 5 | 2,165 | 2,128 | | Property, plant and equipment | | 430 | 521 | | Deferred tax asset | 3 | 156 | 143 | | | | 2,751 | 2,792 | | Current assets | | | | | Prepayments, accrued ...

Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled NUC-7738 plus Pembrolizumab Demonstrated Encouraging Anti-Cancer Activity in Several Patients who were Resistant to PD-1 Inhibitors Anticipated Cash Runway into Q1 2025 EDINBURGH, United Kingdom, May 16, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the first quarter ended March 31, 2024 and provided an update on its broad clinical dev ...

Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled "Our focus remains on advancing our innovative ProTide pipeline to develop more efficacious and safer medicines for patients with cancer," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "NUC-3373, a transformation of 5-FU, is currently being investigated in three ongoing clinical studies. Our randomized Phase 2 study (NuTide:323) is now fully enrolle ...

EDINBURGH, United Kingdom, May 01, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), ("NuCana" or the "Company"), announced that it has received a written notification (the "Notification Letter") from the Listing Qualifications Department of the Nasdaq Stock Market, LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Requirement") and the matter is closed. As ann ...